The Serum Institute of India (SII) ceased Covishield vaccine production following AstraZeneca’s global withdrawal. AstraZeneca cited multiple vaccine options as reason for withdrawal, intending to retract marketing authorizations for Vaxzevria. SII, emphasizing transparency and safety, acknowledged Covishield’s rare side effects. AstraZeneca’s disclosure of vaccine-related thrombosis prompted controversy, leading to vaccine bans in several countries. Despite widespread administration, concerns persist over AstraZeneca’s safety, prompting halts in various nations.